Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 5.9 Million AUD | -56.11% |
| 2023 | 13.45 Million AUD | -27.81% |
| 2022 | 18.63 Million AUD | 336.92% |
| 2021 | 4.26 Million AUD | 27.21% |
| 2020 | 3.35 Million AUD | 45.86% |
| 2019 | 2.29 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 10.89 Million AUD | 62.78% |
| 2024 FY | 18.2 Million AUD | 35.34% |
| 2024 Q1 | 6.69 Million AUD | -15.6% |
| 2024 Q4 | 7.31 Million AUD | 0.0% |
| 2023 Q1 | 3.41 Million AUD | -20.6% |
| 2023 Q4 | 7.92 Million AUD | 69.78% |
| 2023 FY | 13.45 Million AUD | -27.81% |
| 2023 Q3 | 4.67 Million AUD | -15.47% |
| 2023 Q2 | 5.52 Million AUD | 61.78% |
| 2022 Q1 | 3.6 Million AUD | 49.06% |
| 2022 Q4 | 4.3 Million AUD | 30.06% |
| 2022 FY | 18.63 Million AUD | 336.92% |
| 2022 Q3 | 3.3 Million AUD | -21.65% |
| 2022 Q2 | 4.22 Million AUD | 17.13% |
| 2021 Q3 | 3.26 Million AUD | 76.57% |
| 2021 FY | 4.26 Million AUD | 27.21% |
| 2021 Q4 | 2.41 Million AUD | -25.91% |
| 2021 Q2 | 1.84 Million AUD | 18.7% |
| 2021 Q1 | 1.55 Million AUD | 0.0% |
| 2020 FY | 3.35 Million AUD | 45.86% |
| 2019 FY | 2.29 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Australian Clinical Labs Limited | 81.54 Million AUD | 92.758% |
| BCAL Diagnostics Limited | 8.54 Million AUD | 30.893% |
| Genetic Signatures Limited | 4.3 Million AUD | -37.08% |
| Genetic Technologies Limited | 3.9 Million AUD | -51.248% |
| Healius Limited | 265.1 Million AUD | 97.772% |
| Imagion Biosystems Limited | 15.53 Million AUD | 61.985% |
| Integral Diagnostics Limited | 61.88 Million AUD | 90.458% |
| INOVIQ Ltd | 6.8 Million AUD | 13.242% |
| Monash IVF Group Limited | 91.1 Million AUD | 93.518% |
| Rhythm Biosciences Limited | 5.34 Million AUD | -10.385% |
| Sonic Healthcare Limited | 1.49 Billion AUD | 99.605% |